Plasma BNP levels were significantly associated with NYHA functional class in hypertrophic cardiomyopathy (P<0.001), with mean levels of 136, 338, and 481 pg/mL for classes I, II, and III/IV.
Observational (n=107)
Does plasma B-type natriuretic peptide (BNP) assay correlate with symptom severity in patients with hypertrophic cardiomyopathy?
Plasma BNP is independently related to heart failure symptoms in HCM, but its clinical utility is limited by value overlap and confounding by age and wall thickness.
valor p: p=<0.001
BACKGROUND: Hypertrophic cardiomyopathy (HCM) has a diverse clinical spectrum that often includes progressive heart failure symptoms and disability. Assessment of symptom severity may be highly subjective, encumbered by the heterogeneous clinical presentation. Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for heart failure severity and outcome, predominantly in coronary heart disease with ventricular dilatation and systolic dysfunction. METHODS AND RESULTS: We prospectively assessed plasma BNP as a quantitative clinical marker of heart failure severity in 107 consecutive HCM patients. BNP showed a statistically significant relationship to magnitude of functional limitation, assessed by New York Heart Association (NYHA) functional class: I, 136+/-159 pg/mL; II, 338+/-439 pg/mL; and III/IV, 481+/-334 pg/mL (P or =200 pg/mL was the most reliable predictor of heart failure symptoms, with positive and negative predictive values of 63% and 79%, respectively. BNP power in distinguishing patients with or without heart failure symptoms was less than that for differentiating between no (or only mild) and severe symptoms (area under receiver operating characteristic curve=0.75 and 0.83, respectively). CONCLUSIONS: Plasma BNP is independently related to the presence and magnitude of heart failure symptoms in patients with HCM. As a clinical marker for heart failure, BNP is limited by considerable overlap in values between categories of heart failure severity as well as confounding variables of left ventricular wall thickness and age.
Maron et al. (Tue,) conducted a observational in Hypertrophic cardiomyopathy (n=107). Plasma B-type natriuretic peptide (BNP) assay was evaluated on Relationship between BNP and magnitude of functional limitation (NYHA class) (p=<0.001). Plasma BNP levels were significantly associated with NYHA functional class in hypertrophic cardiomyopathy (P<0.001), with mean levels of 136, 338, and 481 pg/mL for classes I, II, and III/IV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: